{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T03:02:17Z","timestamp":1788490937912,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1097\/maj.0b013e3182429866","type":"journal-article","created":{"date-parts":[[2012,1,7]],"date-time":"2012-01-07T12:44:43Z","timestamp":1325940283000},"page":"249-251","source":"Crossref","is-referenced-by-count":26,"title":["Iron Deficiency Anemia Related to Hereditary Hemorrhagic Telangiectasia: Response to Treatment With Bevacizumab"],"prefix":"10.1016","volume":"343","author":[{"given":"Jessica M.","family":"Fleagle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi K.","family":"Bobba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl G.","family":"Kardinal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl E.","family":"Freter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/MAJ.0b013e3182429866_bb0005","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1136\/jmg.29.8.527","article-title":"Hereditary haemorrhagic telangiectasia: a clinical analysis","volume":"29","author":"Porteous","year":"1992","journal-title":"J Med Genet"},{"key":"10.1097\/MAJ.0b013e3182429866_bb0010","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/ajmg.a.10002","article-title":"The prevalence and manifestations of hereditary hemorrhagic telangiectasia in the Afro-Caribbean population of the Netherlands Antilles: a family screening","volume":"116A","author":"Westermann","year":"2003","journal-title":"Am J Med Genet A"},{"key":"10.1097\/MAJ.0b013e3182429866_bb0015","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1101\/gr.5.1.21","article-title":"A second locus for hereditary hemorrhagic telangiectasia maps to chromosome 12","volume":"5","author":"Johnson","year":"1995","journal-title":"Genome Res"},{"key":"10.1097\/MAJ.0b013e3182429866_bb0020","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/ng1294-345","article-title":"Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1","volume":"8","author":"McAllister","year":"1994","journal-title":"Nat Genet"},{"key":"10.1097\/MAJ.0b013e3182429866_bb0025","first-page":"669","article-title":"[Hereditary hemorrhagic telangiectasia (Osler\u2019s disease)]","volume":"117","author":"Romer","year":"1992","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1097\/MAJ.0b013e3182429866_bb0030","first-page":"785","article-title":"Hereditary hemorrhagic telangiectasia: diagnosis and management","volume":"82","author":"Olitsky","year":"2010","journal-title":"Am Fam Physician"},{"key":"10.1097\/MAJ.0b013e3182429866_bb0035","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJM200108023450503","article-title":"Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia","volume":"345","author":"Trembath","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1097\/MAJ.0b013e3182429866_bb0040","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/pmj.79.927.18","article-title":"Hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): a view from the 21st century","volume":"79","author":"Begbie","year":"2003","journal-title":"Postgrad Med J"},{"key":"10.1097\/MAJ.0b013e3182429866_bb0045","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1378\/chest.116.2.432","article-title":"Pulmonary arteriovenous malformations: screening procedures and pulmonary angiography in patients with hereditary hemorrhagic telangiectasia","volume":"116","author":"Kjeldsen","year":"1999","journal-title":"Chest"},{"key":"10.1097\/MAJ.0b013e3182429866_bb0050","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/(SICI)1096-8628(20000306)91:1<66::AID-AJMG12>3.0.CO;2-P","article-title":"Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome)","volume":"91","author":"Shovlin","year":"2000","journal-title":"Am J Med Genet"},{"key":"10.1097\/MAJ.0b013e3182429866_bb0055","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1159\/000262450","article-title":"Antiangiogenic drugs in oncology: a focus on drug safety and the elderly\u2014a mini-review","volume":"56","author":"Boehm","year":"2010","journal-title":"Gerontology"},{"key":"10.1097\/MAJ.0b013e3182429866_bb0060","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ajo.2007.09.031","article-title":"Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study","volume":"145","author":"Bashshur","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1097\/MAJ.0b013e3182429866_bb0065","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1345\/aph.1H316","article-title":"Bevacizumab for neovascular ocular diseases","volume":"41","author":"Lynch","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1097\/MAJ.0b013e3182429866_bb0070","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/lary.20159","article-title":"The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia","volume":"119","author":"Simonds","year":"2009","journal-title":"Laryngoscope"},{"key":"10.1097\/MAJ.0b013e3182429866_bb0075","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00277-006-0147-8","article-title":"Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab","volume":"85","author":"Flieger","year":"2006","journal-title":"Ann Hematol"},{"key":"10.1097\/MAJ.0b013e3182429866_bb0080","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/jmg.2005.030833","article-title":"Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease","volume":"43","author":"Abdalla","year":"2006","journal-title":"J Med Genet"},{"key":"10.1097\/MAJ.0b013e3182429866_bb0085","first-page":"818","article-title":"Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression","volume":"90","author":"Sadick","year":"2005","journal-title":"Haematologica"},{"key":"10.1097\/MAJ.0b013e3182429866_bb0090","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat Med"},{"key":"10.1097\/MAJ.0b013e3182429866_bb0095","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000072411","article-title":"Vascular endothelial growth factor serum levels are elevated in patients with hereditary hemorrhagic telangiectasia","volume":"110","author":"Cirulli","year":"2003","journal-title":"Acta Haematol"},{"key":"10.1097\/MAJ.0b013e3182429866_bb0100","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1172\/JCI18420","article-title":"Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis","volume":"113","author":"Ozawa","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1097\/MAJ.0b013e3182429866_bb0105","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/lt.21417","article-title":"Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia","volume":"14","author":"Mitchell","year":"2008","journal-title":"Liver Transpl"},{"key":"10.1097\/MAJ.0b013e3182429866_bb0110","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1056\/NEJMc0901421","article-title":"Bevacizumab in hereditary hemorrhagic telangiectasia","volume":"360","author":"Bose","year":"2009","journal-title":"N Engl J Med"},{"issue":"suppl","key":"10.1097\/MAJ.0b013e3182429866_bb0115","doi-asserted-by":"crossref","first-page":"e13521","DOI":"10.1200\/jco.2011.29.15_suppl.e13521","article-title":"Iron deficiency anemia related to hereditary hemorrhagic telangiectasia: response to treatment with bevacizumab","volume":"29","author":"Fleagle","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915310260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915310260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,22]],"date-time":"2019-06-22T06:08:18Z","timestamp":1561183698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962915310260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S0002962915310260"],"URL":"https:\/\/doi.org\/10.1097\/maj.0b013e3182429866","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}